Eli Lilly and BI's Jardiance hits shelves

Share this article:
Eli Lilly and BI's Jardiance hits shelves
Eli Lilly and BI's Jardiance hits shelves

Less than a month after FDA approval, BI and Eli Lilly's SGLT-2 inhibitor Jardiance (empagliflozin) is on pharmacy shelves. The drugmakers announced the daily tablet's rollout Tuesday. “Our alliance is proud to make Jardiance available so quickly following its approval by the FDA” BI marketing SVP Kathleen Dowd said in a statement. The 10mg and 25mg tablets are used in tandem with oral hypoglycemic drugs or insulin.

BI and Lilly's candidate is the third in its class: Johnson & Johnson's SGLT-2 inhibitor Invokana (canagliflozin) wrangled the first-in-class approval last year, and was soon followed by AstraZeneca's Farxiga (dapagliflozin). Although Evoke Health's science and medical healthcare VP Brian Whalen said in March that the SGLT-2 category was already crowded, he said Jardiance's profile made it a product to watch. Among its distinguishing characteristics: the FDA has not flagged it for safety concerns, whereas Farxiga has been associated with bladder cancer, and patients with severe liver damage are told to stay away from Invokana.

BI and Lilly are supporting the launch through efforts that include a savings program being promoted online and in physician offices. MM&M also found an informational pamphlet in a dispenser in the cold and flu aisle at a local CVS.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...